“Bimekizumab Versus Secukinumab Continuous Maintenance of PASI 90 and PASI 100 Responses through One Year in Patients With Moderate to Severe Plaque Psoriasis: Post-HOC Results from the BE RADIANT Phase 3b Trial”. SKIN The Journal of Cutaneous Medicine 8, no. 2 (March 18, 2024): s403. Accessed April 18, 2026. https://skin.dermsquared.com/skin/article/view/2731.